Guidant Ancure Adverse Event Reporting Is Focus Of DoJ/FDA Probe
This article was originally published in The Gray Sheet
Executive Summary
Guidant's disclosure of a criminal investigation by the Department of Justice and FDA related to the Ancure abdominal aortic aneurysm endovascular graft comes just one week after the firm highlighted Cook's Zenith AAA device as a key driver of the $3 bil. merger deal
You may also be interested in...
Guidant/EVT Lesson Learned: Post Senior Compliance Execs To Acquired Unit
Integration of a parent firm's adverse event reporting and compliance structure into a subsidiary should begin immediately upon acquisition, as illustrated by Guidant's experience with Menlo Park, Calif. unit Endovascular Technologies
Guidant/EVT Lesson Learned: Post Senior Compliance Execs To Acquired Unit
Integration of a parent firm's adverse event reporting and compliance structure into a subsidiary should begin immediately upon acquisition, as illustrated by Guidant's experience with Menlo Park, Calif. unit Endovascular Technologies
Circulatory Panel’s September Agenda Includes AAA Device Review
W.L. Gore hopes to receive premarket approval for its Excluder abdominal aortic aneurysm repair system by year-end